SenzaGen AB reported consolidated sales results for the first quarter of 2023. Consolidated net sales in the January- March period increased by 36% to SEK 12.3 million driven by strong GARD® sales from new and returning major global customers combined with growth in VitroScreen's innovation services for medical devices, cosmetics and pharmaceuticals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.68 SEK | +2.33% | +10.76% | +32.97% |
25/03 | Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader | CI |
22/03 | SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+32.97% | 2.11Cr | |
-24.86% | 987.42Cr | |
-11.28% | 273.74Cr | |
-12.92% | 223.97Cr | |
-18.21% | 163.37Cr | |
+60.76% | 138.94Cr | |
+24.83% | 77Cr | |
-4.59% | 76Cr | |
-22.45% | 52Cr | |
-0.60% | 31Cr |
- Stock Market
- Equities
- SENZA Stock
- News SenzaGen AB
- SenzaGen AB Reports Consolidated Sales Results for the First Quarter of 2023